Drug Trial Radar · NCT06720025
Study of SAL-0951 Compared to Recombinant Human Erythropoietin in Anemic Patients Receiving Maintenance Hemodialysis
Last checked: Nov 20, 2026Latest source record: Dec 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
100
Actual
Start
Sep 19, 2023
Primary completion
Jun 17, 2024
Study completion Jun 20, 2024
Sponsor
- Lead sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 6, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and efficacy of SAL-0951 in Chinese patients undergoing maintenance hemodialysis with chronic kidney disease and anemia,who are receiving stable treatment with erythropoietic stimulants (ESAs).
Conditions
- Anemia
Interventions
SAL-0951 tabletsDrug
initial phase:4mg QD subsequent phase:1mg~8mg QD,adjust the dose based on hemoglobin concentration level every 4 weeks
rHuEPO injectionDrug
Initial based on the original rHuEPO dose adjust the dose based on hemoglobin concentration level every 4 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Difference in mean hemoglobin (Hb) level between arms during the evaluation period after treatment (non-inferiority margin: -10 g/L)Time frame: weeks 20, 22, and 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.